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This year, the LaskerDeBakey Clinical Medical Research Award will be shared by Mahlon
R. DeLong and Alim-Louis Benabid for elucidating the role of the subthalamic nucleus in mediating
the motor dysfunction of Parkinson’s disease and for pioneering the use of deep-brain stimulation
to alleviate symptoms of the disease.The discovery that deep-brain stimulation
of the subthalamic nucleus can dramati-
cally reduce the life-altering symptoms
of Parkinson’s disease has been ground-
breaking for the fields of neurology
and psychiatry. While L-dopa (Levodopa)
remains the gold standard therapeutic
approach in Parkinson’s disease, the
motor fluctuations associated with it,
together with untoward side effects from
escalating L-dopa therapy, leave many
patients experiencing rigidity and invol-
untary movements. Alternative thera-
peutic approaches are needed. The
LaskerDeBakey Clinical Medical Re-
search Award this year recognizes the
physician-scientists Mahlon DeLong at
Emory University in Atlanta, GA and
Alim-Louis Benabid of the Universite´ Jo-
seph Fourier in Grenoble, France, who
brought forward deep-brain stimulation
as a new and effective therapy that allevi-
ates Parkinson’s disease symptoms and
permits lower doses of L-dopa, thereby
reducing its toxicity. The contributions of
the two awardees represent a wonderful
example of how the interplay between
basic science and medical research can
lead to therapy.
Neurosurgeon Alim-Louis Benabid
noticed that the higher-frequency electri-
cal stimulation that had been traditionally
used to locate targets in the brain that
needed to be ablated to eliminate a
tremor actually mimicked lesioning. Dur-
ing these same years, Mahlon DeLong,
a neurologist, demonstrated that the
symptoms of Parkinson’s disease in the
1-methyl-4-phenyl-1,2,5,6-tetrahydropyr-
idine primatemodel were due to abnormalelectrical activity in the subthalamic nu-
cleus. In fact, DeLong demonstrated that
lesioning the subthalamic nucleus allevi-
ated the symptoms of Parkinson’s dis-
ease in this model. Upon learning about
DeLong’s results, Benabid began to apply
deep-brain stimulation to the subthalamic
nucleus of Parkinson’s patients. Thanks
to these combined efforts, deep-brain
stimulation today is a powerfully effective
therapy for Parkinson’s disease that alle-
viates motor symptoms, allowing medi-
cation doses and their complications to
be reduced and dramatically improving
quality of life in these patients. The work
of DeLong and Benabid has also inspired
research aimed at mapping the circuit
dysfunction in a variety of neuropsychi-
atric disorders in the hope of using
deep-brain stimulation to normalize cir-
cuit activity.
Parkinson’s Disease
Although the disease has been with us
since ancient times, the first systematic
description is credited to James Parkin-
son, a British surgeon, apothecary, pale-
ontologist, and political activist who
published ‘‘An Essay on the Shaking
Palsy’’ in 1817. Parkinson had observed
only three patients—and another three in-
dividuals he ‘‘casually met on the street’’
or ‘‘only [saw] at a distance’’—but these
were sufficient for him to capture the
distinctive motor symptoms that have
defined the disease ever since: ‘‘involun-
tary tremulous motion, with lessened
muscular power, in parts not in action
and even when supported; with a propen-
sity to bend the trunk forward, and to passCell 158, Sepfrom a walking to a running pace: the
senses and intellect being uninjured.’’
The ‘‘lessened muscular power’’ likely
refers to the slowness of movement so
typical of the disease, which is today
referred to as akinesia, hypokinesia, or
bradykinesia; it was this feature that led
him to use the term palsy (paralysis) in
naming the disorder. Parkinson astutely
noted that the tremor occurred when the
body part is at rest and not during an
active movement, that the affected were
all over 50 years of age, and that the dis-
order worsened over time. In 1888, the
French neurologist Jean-Martin Charcot
recognized the importance of Parkinson’s
work and named the disease after him.
Today, parkinsonism is considered a
set of symptoms as well as a disorder
that is defined by any combination of
the following motor abnormalities: resting
tremor, bradykinesia, rigidity, loss of
postural reflexes, flexed posture, and
freezing (an inability to initiate or continue
movement, such as where the feet seem
to be glued to the ground). At least two
of the six criteria are necessary to make
the diagnosis; of these two, one must be
either tremor or bradykinesia.
Parkinsonism is usually idiopathic and
there are a number of risk factors, but
the underlying pathology is consistent. In
1871, the great German-Austrian neuro-
pathologist Theodor Meynert, director of
the Psychiatric Clinic at the University of
Vienna, was the first to recognize the
role of the basal ganglia in disorders of
movement, and American neurologist
Frederic Lewy discovered the presence
of cytoplasmic inclusions, now referredtember 11, 2014 ª2014 Elsevier Inc. 1225
to as Lewy bodies, in postmortem tissues
of Parkinson’s disease cases in 1914.
The Russian neuropathologist Konstantin
Tretiakoff reported on lesions in the
substantia nigra in nine cases of Parkin-
son’s disease in 1919, becoming the first
to link this brain region to the ailment,
and confirmed the presence of Lewy
bodies. In 1957, the Swedish neuroscien-
tist Arvid Carlsson discovered L-dopa, the
precursor to dopamine and norepineph-
rine. His subsequent discoveries that
dopamine is particularly abundant in the
basal ganglia and that L-dopa reverses
reserpine-induced parkinsonism in rab-
bits led him to hypothesize that Parkin-
son’s disease involves some sort of alter-
ation in dopaminergic function. Ehringer
and Hornykiewics then used Carlsson’s
approach for measuring dopamine and
discovered that Parkinson’s disease
causes dopamine deficiency in the stria-
tum, the part of the forebrain that is the
primary input to the basal ganglia.
All of these discoveries laid the founda-
tion for modern therapy of Parkinson
disease. The early symptoms, such as
resting tremor, bradykinesia, and rigidity,
respond to L-dopa and dopamine ago-
nists, and the inclusion of the decarboxy-
lase inhibitor carbidopa prevents dopa-
mine accumulation in peripheral tissues
and lessens L-dopa’s side effects. L-
dopa has its drawbacks, however. First,
it is ineffective against symptoms that
develop as the disease progresses, such
as flexed posture and freezing. Second,
about half of Parkinson’s disease patients
develop disabling fluctuations between
severe parkinsonism (during the wear-
ing-off period) and dyskinesia, especially
after years of Levodopa therapy. Finally,
the action of L-dopa only works as long
as there are some dopaminergic cells
alive. As more of these cells die, the
drug becomes less and less effective.
Clearly, the solution to a dopamine defi-
ciency would not be as straightforward
as adding more dopamine to the system.
DeLong: From Physics to
Neurophysiology
DeLong went to Stanford University with
the intent of becoming an astrophysicist
but found his calling during a required
biology course in his senior year. A post-
graduate year with Don Kennedy in-
troduced him to neuroscience research1226 Cell 158, September 11, 2014 ª2014 Elbefore he headed off to Harvard Medical
School, where clinical encounters during
residency training stirred his interest in
movement disorders. As he pursued
research training in Edward Evarts’ lab
at the National Institute of Mental Health,
he learned to perform single-cell record-
ings from intact behaving primates and
to correlate the activity of individual neu-
rons with movements of different body
parts. Since others in the lab were already
working on the motor cortex and the cer-
ebellum, DeLong chose to explore the
relatively unknown territory of the basal
ganglia. To his surprise, he did not find
the activity of basal ganglia cells to corre-
late with the initiation of movements. It
took several more years of investigation
to reveal that the basal ganglia are more
involved in the execution rather than in
the initiation of movement (Delong et al.,
1984).
A decade of further research on the
functional organization of the basal
ganglia led him to propose that these
neurons belong to multiple parallel
but segregated basal ganglia-thalamo-
cortical circuits, each of which engages
a specific region (of the cerebral cortex,
striatum, pallidum, substantia nigra, or
thalamus) and projects back to one of
the cortical areas providing input to the
circuit to form a partially closed loop
(Alexander et al., 1986). This profoundly
altered the prevailing view of the basal
ganglia, which had been considered to
be involved primarily in movement; De-
Long’s work showed them to be involved
in cognition and emotion as well. DeLong
did not expect the anatomical studies
to have a practical impact on clinical
management, but a sociological phenom-
enon altered the course of his work and
broadened the landscape of Parkinson’s
disease research. It was the mid-1970s,
and it had to do with drugs—street drugs,
that is.
A booming market led to a heroin
shortage, so drug dealers started con-
cocting the synthetic opioid 1-methyl-4-
phenyl-4-propionoxypiperidine (MPPP).
Curiously, MPPP users sometimes devel-
oped severe parkinsonism: apparently,
careless street chemists were acci-
dentally concocting the closely related
1-methyl-4-phenyl-1,2,5,6-tetrahydropyr-
idine (MPTP) instead. MPTP is metabo-
lized into the neurotoxin 1-methyl-4-phe-sevier Inc.nylpyridinium (MPP+), which interferes
with complex I of the electron transfer
chain, causing mitochondrial dysfunction
and selective degeneration of the neu-
rons of the substantia nigra (Langston
et al., 1983). Soon intravenous injection
of MPTP was used to develop a rhesus
monkey model of parkinsonism. The
monkeys developed the hallmark features
of idiopathic Parkinson’s disease, degen-
eration of the substantia nigra and reduc-
tion of striatal dopamine (Burns et al.,
1983). The availability of a nonhuman
primate model for parkinsonism allowed
DeLong and others to delve into the path-
ophysiology of basal ganglia dysfunction.
DeLong focused on the African green
monkey because it exhibited a resting
tremor in addition to the other clinicopath-
ological features.
It was generally believed at that
time that Parkinson’s disease symptoms
were attributable to impaired activity in
the globus pallidus, which represents the
major output of the basal ganglia motor
circuit (Figure 1). Much to everyone’s
surprise, DeLong and colleagues found
that, in MPTP-treated monkeys, the tonic
neuronal discharges of the internal globus
pallidus and the subthalamic nucleus
that projects to it were actually increased
(Miller and DeLong, 1987). Conversely,
the tonic neuronal discharges of the
external segment of the globus pallidus
were decreased. These findings are
consistent with evidence that loss of stria-
tal dopamine results in increased trans-
mission through the indirect (putamen/
external globus pallidus/subthalamic
nucelus/internal globus pallidus)
pathway and decreased transmission
through the direct pathway (putamen/
external globus pallidus). The net result
from such altered transmission would be
excessive tonic and phasic inhibition of
the thalamic-cortical pathway (Figure 1).
The reduction in cortical activation ex-
plains some of the ‘‘negative’’ signs of
Parkinson’s disease, such as akinesia
and rigidity. The discovery that increased
subthalamic nucleus activity contributes
to the excessive inhibitory output of the
internal globus pallidus pinpointed the
subthalamic nucleus as a key node in
the circuit dysfunction underlying the dis-
order. From here, it was a short step to the
hypothesis that lesioning the subthalamic
nucleus should improve MPTP-induced
Figure 1. Neural Circuits Affected in Parkinson’s Disease
The schematic depicts the direct and indirect basal ganglia thalamocortical circuit, its disruption in Par-
kinson’s disease, and the effect of inhibiting the subthalamic nucleus using deep-brain stimulation.
(A) The circuit in healthy individuals. Green arrows represent excitatory connections; block lines represent
inhibitory connections. SNC, substantia nigra pars compacta; VL, ventrolateral; GPe, external segment of
the globus pallidus; GPi, internal segment of the globus pallidus; STN, subthalamic nucleus.
(B) Parkinson’s disease causes loss of SNC neurons, resulting in decreased inhibitory output from pu-
tamen to GPi and increased inhibition onto GPe. Excess inhibition of GPe leads to reduced inhibition of the
STN and, in turn, increases excitatory drive from STN onto GPi. The enhanced GPi output overinhibits the
VL thalamus, causing decreased thalamic-cortical activity.
(C) High-frequency deep-brain stimulation restores some functionality to the circuit in Parkinson’s disease
by inactivating the STN.
Figure adapted from Bergman et al. (1990).parkinsonism. The DeLong team injected
ibotenic acid into the subthalamic nucleus
of two African green monkeys with akine-
sia, tremor, and rigidity secondary to
MPTP injection. The response to subtha-
lamic nucleus lesioning was remarkable:
within minutes, both monkeys moved
their contralateral extremities, purposeful
movements ensued, and the tremors dis-
appeared (Bergman et al., 1990). There
was also transient dyskinesia of the limbs
contralateral to the subthalamic nucleus
lesions. The reversal of akinesia upon
subthalamic nucleus lesioning supported
the notion that this negative symptom re-
sults from excess subthalamic nucleus
and internal globus pallidus activity. The
effect of subthalamic nucleus lesions
on the tremor was quite unexpected and
suggested that this symptom results
from basal ganglia circuit dysfunction.
Benabid: From Physics to
Electrophysiology
Like DeLong, Alim-Louis Benabid, son of
an Algerian physician, also loved both
physics and medicine. He earned hismedical degree in 1970 at Universite´
Joseph Fourier in Grenoble, became a
staff neurosurgeon there, and then earned
his doctorate in physics in his spare time
from the same university in 1978. As a
surgeon, Benabid made improvements
to stereotactic surgical methods for brain
tumors and movement disorders, using
electrical stimulation to map the precise
site to create a lesion. For example,
patients with severe, treatment-resistant
tremors could find relief through thala-
motomy of the thalamic nucleus ventralis
intermedius. Although electrical stimula-
tion had been used in patients with
neuropsychiatric or pain disorders in the
1960s and 1970s (Lozano and Lipsman,
2013), these were limited studies without
detailed mapping of the neurocircuitry or
blinded assessment of the effects of elec-
trical neuromodulation. Benabid noticed
that, when he used electrical stimulation
to locate the precise lesion target in the
thalamus in the awake patient, sometimes
it quieted the tremor even before lesion-
ing. He realized that electrical stimulation
itself might be a viable treatment and setCell 158, Sepabout systematically testing frequencies
ranging from 1 Hz up to 100 Hz. He soon
discovered that stimulation of the ventra-
lis intermedius nucleus at 100 Hz consis-
tently suppressed tremors (Benabid
et al., 1987). Although thalamotomy
helped many patients, its irreversibility,
the recurrence of the tremor in about
20% of the patients, and the greater risk
of adverse effects in individuals over 65
years old made exploring chronic stimula-
tion of the ventralis intermedius nucleus a
promising alternative therapy. A study of
26 patients with Parkinson’s disease and
six with essential tremor demonstrated a
high rate of complete relief from the
tremor, reliable safety, and reversibility
(in case of mild adverse effects), making
thalamic stimulation superior to the thala-
motomy, especially when the symptoms
are bilateral (Benabid et al., 1991).
The next step was exploring this
approach beyond the thalamus. If lesions
of the subthalamic nucleus can reverse
parkinsonism in MPTP-treated monkeys,
as DeLong had shown, could bilateral
subthalamic nucleus stimulation benefit
human patients? The first human study
was a pilot in three individuals with severe
akinesia and rigidity. Given the small num-
ber of patients, the only firm conclusion
that could be drawn was that the sub-
thalamic nucleus is important in driving
Parkinson’s disease symptoms (Limousin
et al., 1995).
Benabid then went on to do the key
study that demonstrated the benefits of
subthalamic nucleus stimulation in 24
patients with advanced Parkinson’s dis-
ease; 20 of these patients were followed
for 12 months. Electrical stimulation
of the subthalamic nucleus significantly
improved their motor functioning—
reducing rigidity, tremor, and akinesia
and restoring a more fluid gait—and this
allowed the dose of dopaminergic
medication to be reduced by half. One
individual developed a hematoma, the
only serious adverse effect observed.
This study not only validated DeLong’s
predictions made 8 years previously but
proved the relative safety, reliability, and
efficacy of this adjunct therapy for pa-
tients with advanced Parkinson’s disease
(Limousin et al., 1998). Long-term follow-
up on 49 Parkinson’s disease patients
treated with bilateral stimulation of the
subthalamic nucleus revealed that motortember 11, 2014 ª2014 Elsevier Inc. 1227
function improved over 5 years, especially
when off medication. For individuals on
medication, the dose of dopaminergic
therapy and the L-dopa-induced dyski-
nesia were greatly reduced (Krack et al.,
2003).
Benabid is thus credited with providing
the impetus to move from lesioning to
electrical stimulation and for performing
controlled studies to evaluate the neuro-
modulatory effects of deep-brain stimula-
tion in Parkinson’s disease. Today, the
procedure for deep-brain stimulation is
much the same: electrode leads are
implanted via burr holes in the skull using
imaging-guided stereotactic neurosur-
gery in an awake patient so that the stim-
ulation target can be precisely mapped.
An extension runs under the scalp to
connect the leads to a subcutaneous
implanted pulse generator containing a
small battery-operated computer, which
can be adjusted by an external handheld
computer interface to set and modify the
stimulation parameters. Stimulation can
be immediately turned off in case of an
adverse effect—an advantage over even
pharmacotherapy. The FDA approved
deep-brain stimulation for Parkinson’s
disease in 2002.
Deep-Brain Stimulation: From Hope
to Reality
To date, more than 100,000 individuals
with advanced Parkinson’s disease have
undergone deep-brain stimulation of the
subthalamic nucleus. Various randomized
controlled trials comparing deep-brain
stimulation plus medication against medi-
cation alone have established that deep-
brain stimulation significantly improves
motor symptoms, functionality, and qual-
ity of life. It is particularly noteworthy that
the improvement of functionality extends
to the ‘‘off medication’’ period, as is the
fact that the dose of required dopami-
nergic drugs can be reduced—along
with their associated adverse effects. At
this time, however, deep-brain stimulation
has no demonstrated benefits on cog-
nition. Risks associated with DBS include
the typical complications associated with
anesthesia and surgery, such as hemor-
rhage and infection.
The precise area to be stimulated de-
pends on the predominant symptom
interfering with the patient’s quality of
life. Stimulation of the internal segment1228 Cell 158, September 11, 2014 ª2014 Elof the globus pallidus and subthalamic
nucleus is used to treat rigidity, akinesia,
tremor, and dopamine-induced involun-
tary movements. Deep-brain stimulation
of the ventral intermediate nucleus of the
thalamus is reserved for Parkinson’s dis-
ease patients whose most disturbing
feature is the tremor as well as for patients
with essential tremor. None of these areas
help the gait disturbances in Parkinson’s
disease, however. The pedunculopontine
nucleus, a brain stem structure that re-
ceives input from the basal ganglia and
the spinal cord, is emerging as a new
potential target area: early data suggest
that unilateral pedunculopontine nucleus
stimulation enhances postural stability.
There are nowmore than 280 registered
clinical trials in different stages testing
the safety and potential efficacy of deep-
brain stimulation for a variety of condi-
tions (http://www.clinicaltrials.gov). Given
the benefits of deep-brain stimulation for
tremor, rigidity, and involuntary move-
ments, it is not surprising that deep-brain
stimulation is being evaluated as adjunct
therapy for several movement disorders
besides Parkinson’s disease. These clin-
ical entities include primary and second-
ary dystonia and tremors arising from
diverse causes. The benefits to patients
with primary dystonia, though typically
delayed for days to weeks, are impressive
(Isaias et al., 2009) and led the FDA to
approve a Humanitarian Device exemp-
tion for dystonia in 2003.
What is more surprising is the beneficial
effect of deep-brain stimulation in psychi-
atric and cognitive disorders, which can
be notoriously resistant to treatment.
Where neuroimaging data can point to
specific dysfunctional circuits, there is
the potential that deep-brain stimula-
tion might provide relief. In obsessive
compulsive disorder, for example, studies
suggest malfunction in the cortical-stria-
tal-thalamic-cortical circuits. The FDA
approved a Humanitarian Device exemp-
tion for the use of deep-brain stimulation
to treat obsessive compulsive disorder in
2009; studies stimulating the subthalamic
nucleus, ventral striatum, and ventral
capsule are still ongoing to map the ideal
target for stimulation and establish its
efficacy.
Major depressive disorder is a common
illness that presents a treatment chal-
lenge in the approximately one-third ofsevier Inc.patients who receive no benefit from
either pharmacological or behavioral ther-
apies, alone or in combination. Functional
imaging of patients with major depressive
disorder has pointed to the subcallosal
cingulate area (typically activated by
sadness) as being hypermetabolic, and
at least a subset of major depressive
disorder patients respond to deep-brain
stimulation of the subcallosal cingulated
(Riva-Posse et al., 2014). Though it is still
too early to tell whether deep-brain stimu-
lation of subcallosal cingulate will have
broader applicability in major depressive
disorder, the combination of patient
assessment, genetic studies, functional
imaging, and data collected during elec-
trode placement testing has the potential
to augment our understanding of major
depressive disorder and define the
parameters for deep-brain stimulation
intervention.
Most recently, two new deep-brain
stimulation paradigms are being explored
in Alzheimer’s disease. The first approach
involves stimulation of the nucleus basalis
of Meynert to enhance cholinergic activ-
ity, and the second involves forniceal
stimulation in hope of enhancing activity
in the circuit of Papez, which is involved
in memory retrieval. Both of these trials
are still in the early stages, but the im-
provements in cognition and increased
cerebral metabolism observed in posi-
tion-emission tomography are promising
(Smith et al., 2012).
Collective Progress
The awardees and the work of others
who followed in their footsteps leave the
neuroscience community with two gifts.
First, the transition from ablation to
deep-brain stimulation has revived func-
tional neurosurgery for neuropsychiatric
disorders. Second, the power of deep-
brain stimulation lies not only in its
use as an effective therapy for disabling
neurological (and possibly psychiatric)
symptoms, but also in its potential to
probe neural circuits. The ability to use
deep-brain stimulation microelectrodes
to record from neurons of awake patients
both at rest and in response to motor or
cognitive tasks provides a wonderful op-
portunity to begin to map the circuitry un-
derlying specific behaviors (Lozano and
Lipsman, 2013) in humans. Just as the
development of deep-brain stimulation
for Parkinson’s disease involved interplay
between various fields, we should view
the outcomes of ‘‘translational’’ research
not as static endpoints but as dynamic
generators of new knowledge in a schol-
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